Skip to main content

Cara Therapeutics, Inc. (CARA)

NASDAQ: CARA · IEX Real-Time Price · USD
15.58 0.27 (1.76%)
Sep 21, 2021 1:35 PM EDT - Market open
Market Cap766.88M
Revenue (ttm)123.29M
Net Income (ttm)8.35M
Shares Out50.06M
EPS (ttm)0.17
PE Ratio91.65
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume343,177
Open15.40
Previous Close15.31
Day's Range15.27 - 15.62
52-Week Range11.22 - 29.65
Beta1.07
AnalystsBuy
Price Target26.33 (+69.0%)
Est. Earnings DateNov 8, 2021

About CARA

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-assoc...

IndustryPharmaceuticals
IPO DateJan 31, 2014
CEODerek Chalmers
Employees80
Stock ExchangeNASDAQ
Ticker SymbolCARA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CARA stock is "Buy." The 12-month stock price forecast is 26.33, which is an increase of 69.00% from the latest price.

Price Target
$26.33
(69.00% upside)
Analyst Consensus: Buy

News

Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval

There's good news at long last for the beaten-down biotech stock.

2 weeks ago - The Motley Fool

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...

Other symbols:ASNDJAZZSESNSNY
2 weeks ago - Benzinga

Why Cara Therapeutics Shot Higher Today

The biotech gets an important nod from a top regulator.

3 weeks ago - The Motley Fool

CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today

Shares of CARA stock are ticking higher on Tuesday after the Cara Therapeutics' injection treatment was approved by the FDA. The post CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing...

3 weeks ago - InvestorPlace

Biotech Stock Takes on Technical Ceiling After FDA Okay

Care Therapeutics Inc (NASDAQ:CARA) is seeing a influx of options activity today, following news that the U.S. Food and Drug Administration (FDA) approved its Korsuva difelikefalin injection to treat mo...

3 weeks ago - Schaeffers Research

CARA Drug Wins FDA Nod for Pruritus Associated With CKD

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

Other symbols:HZNPREGNRGEN
4 weeks ago - Zacks Investment Research

Why Is Cara Therapeutics Stock Trading Higher Today?

Cara Therapeutics Inc (NASDAQ: CARA) is trading higher Tuesday after the company, and Vifor Pharma, announced the U.S. Food and Drug Administration approved KORSUVA for injection for the treatment of mo...

4 weeks ago - Benzinga

See Why Cara Therapeutics (CARA) Stock Is Moving Higher On Tuesday

The FDA has approved Cara Therapeutics Inc (NASDAQ: CARA) and Vifor Pharma AG's Korsuva (difelikefalin) injection for severe-to-moderate pruritis (itching) in patients with chronic kidney disease (CKD) ...

4 weeks ago - Benzinga

Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-...

ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Cara Therapeutics (Nasdaq:CARA) today announced that the U.S. Food and Drug Administration (FDA) has approve...

4 weeks ago - Business Wire

These 2 Stocks Just Soared After Hours Monday

After a record-setting day, the news for these two companies was icing on the cake.

Other symbols:PANW
4 weeks ago - The Motley Fool

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment...

STAMFORD, Conn. and ST. GALLEN, Switzerland, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has appr...

4 weeks ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Cara Therapeutics (CARA) Reports Q2 Loss, Misses Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -10.91% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Cara Therapeutics: Q2 Earnings Insights

Shares of Cara Therapeutics (NASDAQ:CARA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 12.96% year over year to ($0.61), which ...

1 month ago - Benzinga

Cara Therapeutics Reports Second Quarter 2021 Financial Results

– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 –

1 month ago - GlobeNewsWire

Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

STAMFORD, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...

1 month ago - GlobeNewsWire

How to Buy Biotech Stocks This Summer

It pays to know what could cause them to move and when.

Other symbols:BIIBOCGN
3 months ago - The Motley Fool

Is Cara Therapeutics a Buy for Summer 2021?

The future of this troubled clinical-stage biotech rests on a single drug candidate that management hopes will treat an extremely common condition.

3 months ago - The Motley Fool

12 Cannabis Stocks That Lit Up Wall Street This Week

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

3 months ago - Schaeffers Research

Is Cara Therapeutics a Buy?

Maybe, if you're itching to speculate.

3 months ago - The Motley Fool

Here Are the Cannabis Stocks That Caught Fire This Week

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

4 months ago - Schaeffers Research

Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 24.19% and -80.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Cara Therapeutics: Q1 Earnings Insights

Shares of Cara Therapeutics (NASDAQ:CARA) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 24.19% year over year to ($0.47), which beat ...

4 months ago - Benzinga

Cara Therapeutics Reports First Quarter 2021 Financial Results

– U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA™ Injection in CKD-aP –

4 months ago - GlobeNewsWire